SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 61.9% in December

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 155,400 shares, a growth of 61.9% from the November 30th total of 96,000 shares. Based on an average daily volume of 725,400 shares, the short-interest ratio is currently 0.2 days. Approximately 1.5% of the company’s stock are short sold.

SciSparc Price Performance

NASDAQ SPRC traded down $0.07 during mid-day trading on Friday, reaching $0.43. 8,035,851 shares of the company’s stock traded hands, compared to its average volume of 2,476,734. SciSparc has a 1-year low of $0.20 and a 1-year high of $6.78. The company has a fifty day simple moving average of $0.24 and a 200-day simple moving average of $0.39.

Hedge Funds Weigh In On SciSparc

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC purchased a new stake in SciSparc Ltd. (NASDAQ:SPRC) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned approximately 5.59% of SciSparc at the end of the most recent reporting period. Institutional investors own 25.06% of the company’s stock.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.